Riepilogo
pazienti trattati
Qualcuno ha mai tratto beneficio dalle cellule staminali?
Per la prima volta, le cellule staminali del cordone ombelicale sono state utilizzate con successo nel 1988 in Francia. Diversi anni dopo, nel 2007, questo metodo è stato introdotto anche dal Gruppo FamiCord in Polonia. Ad oggi, le cellule staminali del cordone ombelicale sono state trapiantate oltre 40.000 volte in tutto il mondo, salvando vite e salute a molte persone.
Il Gruppo FamiCord offre ai propri clienti trattamenti innovativi con le cellule staminali. Consulta l'elenco completo dei pazienti, affetti da diverse patologie, che ne hanno beneficiato.
Elenco dei pazienti
| NO. | Fonte | Tipo di fonte | Diagnosi | Settore medico | Anno di applicazione | Terapia | Paese | Età del destinatario |
|---|---|---|---|---|---|---|---|---|
| 2301 | Apheresis | Allogenico | Sindrome mielodisplasica | Ematologia | 2021 | Terapia standard | Poland | 70 |
| 2302 | Apheresis | Allogenico | Sindrome mielodisplasica | Ematologia | 2021 | Terapia standard | Poland | 8 |
| 2303 | Apheresis | Allogenico | Sindrome mielodisplasica | Ematologia | 2021 | Terapia standard | Poland | 66 |
| 2304 | Apheresis | Allogenico | Sindrome mielodisplasica | Ematologia | 2021 | Terapia standard | Poland | 26 |
| 2305 | Apheresis | Allogenico | Sindrome mielodisplasica | Ematologia | 2021 | Terapia standard | Poland | 56 |
| 2306 | Apheresis | Allogenico | Sindrome mielodisplasica | Ematologia | 2021 | Terapia standard | Poland | 63 |
| 2307 | Apheresis | Allogenico | Sindrome mielodisplasica | Ematologia | 2021 | Terapia standard | Poland | 61 |
| 2308 | Apheresis | Allogenico | Sindrome mielodisplasica | Ematologia | 2021 | Terapia standard | Poland | 70 |
| 2309 | Apheresis | Allogenico | Sindrome mielodisplasica | Ematologia | 2021 | Terapia standard | Poland | 66 |
| 2310 | Apheresis | Allogenico | Sindrome mielodisplasica | Ematologia | 2021 | Terapia standard | Germania | 48 |
| 2311 | Apheresis | Allogenico | Sindrome mielodisplasica | Ematologia | 2021 | Terapia standard | Germania | 58 |
| 2312 | Apheresis | Allogenico | Sindrome mielodisplasica | Ematologia | 2021 | Terapia standard | Germania | 59 |
| 2313 | Apheresis | Allogenico | Mielofibrosi | Ematologia | 2021 | Terapia standard | Poland | 62 |
| 2314 | Apheresis | Allogenico | Mielofibrosi | Ematologia | 2021 | Terapia standard | Poland | 63 |
| 2315 | Apheresis | Allogenico | Mielofibrosi | Ematologia | 2021 | Terapia standard | Poland | 64 |
| 2316 | Apheresis | Allogenico | Mielofibrosi | Ematologia | 2021 | Terapia standard | Poland | 66 |
| 2317 | Apheresis | Allogenico | Mielofibrosi | Ematologia | 2021 | Terapia standard | Poland | 65 |
| 2318 | Apheresis | Allogenico | Mielofibrosi | Ematologia | 2021 | Terapia standard | Poland | 56 |
| 2319 | Apheresis | Allogenico | Myelofibrosis With Myeloid Metaplasia | Ematologia | 2021 | Terapia standard | Poland | 75 |
| 2320 | Apheresis | Allogenico | Myelofibrosis With Myeloid Metaplasia | Ematologia | 2021 | Terapia standard | Poland | 65 |
| 2321 | Apheresis | Allogenico | Myelofibrosis With Myeloid Metaplasia | Ematologia | 2021 | Terapia standard | Poland | 51 |
| 2322 | Apheresis | Allogenico | Myelofibrosis With Myeloid Metaplasia | Ematologia | 2021 | Terapia standard | Poland | 63 |
| 2323 | Apheresis | Allogenico | Myelofibrosis With Myeloid Metaplasia | Ematologia | 2021 | Terapia standard | Poland | 75 |
| 2324 | Apheresis | Allogenico | Myelofibrosis With Myeloid Metaplasia | Ematologia | 2021 | Terapia standard | Poland | 64 |
| 2325 | Apheresis | Allogenico | Myeloma Multiplex | Ematologia | 2021 | Terapia standard | Poland | 48 |
| 2326 | Apheresis | Allogenico | Myeloma Multiplex | Ematologia | 2021 | Terapia standard | Poland | 53 |
| 2327 | Apheresis | Allogenico | Myeloproliferative Neoplasms | Ematologia | 2021 | Terapia standard | Poland | 67 |
| 2328 | Apheresis | Allogenico | Myeloproliferative Neoplasms | Ematologia | 2021 | Terapia standard | Poland | 58 |
| 2329 | Apheresis | Allogenico | Myeloproliferative Neoplasms | Ematologia | 2021 | Terapia standard | Germania | 51 |
| 2330 | Apheresis | Allogenico | No Data | Ematologia | 2021 | Terapia standard | Poland | 64 |
| 2331 | Apheresis | Allogenico | No Data | Ematologia | 2021 | Terapia standard | Poland | 57 |
| 2332 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2021 | Terapia standard | Poland | 30 |
| 2333 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2021 | Terapia standard | Poland | 51 |
| 2334 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2021 | Terapia standard | Poland | 58 |
| 2335 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2021 | Terapia standard | Poland | 56 |
| 2336 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2021 | Terapia standard | Poland | 58 |
| 2337 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2021 | Terapia standard | Poland | 50 |
| 2338 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2021 | Terapia standard | Poland | 53 |
| 2339 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2021 | Terapia standard | Poland | 20 |
| 2340 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2021 | Terapia standard | Poland | 64 |
| 2341 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2021 | Terapia standard | Poland | 66 |
| 2342 | Apheresis | Allogenico | Linfoma non-Hodgkin | Ematologia | 2021 | Terapia standard | Germania | 62 |
| 2343 | Apheresis | Autologo | Linfoma non-Hodgkin | Ematologia | 2021 | Terapia standard | Germania | 61 |
| 2344 | Apheresis | Autologo | Linfoma non-Hodgkin | Ematologia | 2021 | Terapia standard | Germania | 49 |
| 2345 | Apheresis | Allogenico | Non-Hodgkin-Lymphoma-Relapse | Ematologia | 2021 | Terapia standard | Germania | 62 |
| 2346 | Apheresis | Allogenico | Osteomyelitis | Ematologia | 2021 | Terapia standard | Poland | 47 |
| 2347 | Apheresis | Allogenico | Osteomyelofibrosis | Ematologia | 2021 | Terapia standard | Poland | 69 |
| 2348 | Apheresis | Allogenico | Osteomyelofibrosis | Ematologia | 2021 | Terapia standard | Poland | 43 |
| 2349 | Apheresis | Autologo | Osteosclerotic Myeloma | Ematologia | 2021 | Terapia standard | Germania | 54 |
| 2350 | Apheresis | Allogenico | Other Myelodysplastic Syndromes | Ematologia | 2021 | Terapia standard | Poland | 65 |
| 2351 | Apheresis | Allogenico | Other Myelofibrosis | Ematologia | 2021 | Terapia standard | Poland | 68 |
| 2352 | Apheresis | Allogenico | Other Myelofibrosis | Ematologia | 2021 | Terapia standard | Poland | 70 |
| 2353 | Apheresis | Allogenico | Other Myelofibrosis | Ematologia | 2021 | Terapia standard | Poland | 72 |
| 2354 | Apheresis | Allogenico | Other Plasma Cell Disorder | Ematologia | 2021 | Terapia standard | Poland | 67 |
| 2355 | Apheresis | Allogenico | Peripheral T-Cell Lymphoma | Ematologia | 2021 | Terapia standard | Poland | 45 |
| 2356 | Apheresis | Allogenico | Philadelphia-Positive Acute Lymphoblastic Leukemia | Ematologia | 2021 | Terapia standard | Poland | 61 |
| 2357 | Apheresis | Allogenico | Polycythemia Vera | Ematologia | 2021 | Terapia standard | Poland | 65 |
| 2358 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 71 |
| 2359 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 66 |
| 2360 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 62 |
| 2361 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 53 |
| 2362 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 44 |
| 2363 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 54 |
| 2364 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 65 |
| 2365 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 65 |
| 2366 | Apheresis | Autologo | Primary Central Nervous System Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 60 |
| 2367 | Apheresis | Allogenico | Mielofibrosi primaria | Ematologia | 2021 | Terapia standard | Poland | 66 |
| 2368 | Apheresis | Allogenico | Mielofibrosi primaria | Ematologia | 2021 | Terapia standard | Poland | 63 |
| 2369 | Apheresis | Allogenico | Mielofibrosi primaria | Ematologia | 2021 | Terapia standard | Poland | 62 |
| 2370 | Apheresis | Allogenico | Mielofibrosi primaria | Ematologia | 2021 | Terapia standard | Poland | 64 |
| 2371 | Apheresis | Allogenico | Prolymphocytic Leukemia | Ematologia | 2021 | Terapia standard | Poland | 68 |
| 2372 | Apheresis | Allogenico | Prolymphocytic Leukemia | Ematologia | 2021 | Terapia standard | Poland | 64 |
| 2373 | Apheresis | Allogenico | Refractory Cytopenia | Ematologia | 2021 | Terapia standard | Poland | 6 |
| 2374 | Apheresis | Allogenico | Secondary Acute Lymphoblastic Leukemia From Chronic Myeloid Leukemia | Ematologia | 2021 | Terapia standard | Poland | 58 |
| 2375 | Apheresis | Allogenico | Secondary Acute Myeloid Leukemia | Ematologia | 2021 | Terapia standard | Germania | 70 |
| 2376 | Apheresis | Allogenico | Secondary Acute Myeloid Leukemia | Ematologia | 2021 | Terapia standard | Germania | 64 |
| 2377 | Apheresis | Allogenico | Secondary Acute Myeloid Leukemia | Ematologia | 2021 | Terapia standard | Germania | 39 |
| 2378 | Apheresis | Allogenico | Secondary Acute Myeloid Leukemia | Ematologia | 2021 | Terapia standard | Germania | 60 |
| 2379 | Apheresis | Allogenico | Anemia aplastica grave | Ematologia | 2021 | Terapia standard | Poland | 35 |
| 2380 | Apheresis | Allogenico | Anemia aplastica grave | Ematologia | 2021 | Terapia standard | Poland | 58 |
| 2381 | Apheresis | Allogenico | Anemia aplastica grave | Ematologia | 2021 | Terapia standard | Poland | 41 |
| 2382 | Apheresis | Allogenico | Anemia aplastica grave | Ematologia | 2021 | Terapia standard | Poland | 38 |
| 2383 | Apheresis | Allogenico | Immunodeficienza combinata grave | Ematologia | 2021 | Terapia standard | Poland | 1 |
| 2384 | Apheresis | Allogenico | Immunodeficienza combinata grave | Ematologia | 2021 | Terapia standard | Poland | 1 |
| 2385 | Apheresis | Allogenico | T-Cell Lymphoblastic Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 26 |
| 2386 | Apheresis | Allogenico | T-Cell Lymphoblastic Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 37 |
| 2387 | Apheresis | Autologo | T-Cell Non-Hodgkin Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 54 |
| 2388 | Apheresis | Autologo | T-Cell Non-Hodgkin Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 66 |
| 2389 | Apheresis | Autologo | T-Cell Non-Hodgkin Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 66 |
| 2390 | Apheresis | Autologo | T-Cell Non-Hodgkin Lymphoma | Ematologia | 2021 | Terapia standard | Germania | 29 |
| 2391 | Apheresis | Allogenico | T-Cell-Lymphoma | Ematologia | 2021 | Terapia standard | Poland | 45 |
| 2392 | Apheresis | Autologo | Testicular Cancer | Ematologia | 2021 | Terapia standard | Germania | 33 |
| 2393 | Apheresis | Allogenico | Β – Thalassemia | Ematologia | 2021 | Terapia standard | Poland | 17 |
| 2394 | Adipose Tissue | Autologo | Gonarthrosis | Ortopedia | 2021 | Terapia sperimentale | Poland | 51,1 |
| 2395 | Adipose Tissue | Autologo | Gonarthrosis | Ortopedia | 2021 | Terapia sperimentale | Poland | 44,4 |
| 2396 | Adipose Tissue | Autologo | Gonarthrosis | Ortopedia | 2021 | Terapia sperimentale | Poland | 35,8 |
| 2397 | Adipose Tissue | Autologo | Internal Damage To The Knee Joint | Ortopedia | 2021 | Terapia sperimentale | Poland | 40.9 |
| 2398 | Adipose Tissue | Autologo | Soft Tissue Diseases Related To Use, Overload And Pressure | Ortopedia | 2021 | Terapia sperimentale | Poland | 27,5 |
| 2399 | Placenta blood | Autologo | Paralisi cerebrale | Neurologia | 2020 | Terapia sperimentale | Poland | 2,6 |
| 2400 | Tessuto del cordone ombelicale | Allogenico – Non correlato | Covid-19 | Pulmonology | 2020 | Terapia sperimentale | Poland | 84,5 |